Tavr with sapien 3 demonstrated as economically dominant treatment strategy compared to surgery in partner 3 analysis

Irvine, calif., nov. 5, 2021 /prnewswire/ -- edwards lifesciences (nyse: ew) today announced that a cost-effectiveness analysis comparing transcatheter aortic valve replacement (tavr) to surgery demonstrated that tavr with sapien 3 is an economically dominant treatment strategy, offering improved outcomes and reduced cost.
EW Ratings Summary
EW Quant Ranking